Inactive Instrument

Highlights Imago BioSciences, Inc.

Equities

IMGO

US45250K1079

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Merck & Company Concludes Cash Tender Offer to Acquire Imago BioSciences	11/23/11	MT
Merck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc..	11/23/11	CI
Imago BioSciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis	21/22/21	CI
Imago BioSciences Reports 'Positive' Mid-Stage Results in Thrombocythemia Trial	13/22/13	MT
Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022	12/22/12	CI
Merck Begins Tender Offer to Acquire Imago BioSciences	12/22/12	MT
Iimago Biosciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia	01/22/01	CI
Merck & Co. To Buy Bone Marrow Disease-focused Imago BioSciences For $1.4 Billion	22/22/22	MT
Trending : Merck to Acquire Imago BioSciences for $1.35 Billion	22/22/22	DJ
Merck Eyes Expanded Blood Disorder Drug Pipeline Via $1.35 Billion Buyout of Imago BioSciences	21/22/21	MT
Imago BioSciences Shares Take Flight on Takeover by Merck	21/22/21	DJ
Exchange-Traded Funds Preview: ETFs, Stock Futures Mixed After Chicago Fed National Index Report	21/22/21	MT
Merck to Buy Imago for $36 A Share, More Than Double Friday's Close	21/22/21	DJ
Merck to Acquire Imago BioSciences in $1.35 Billion Deal; Imago Shares Surge Pre-Bell	21/22/21	MT
Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs	21/22/21	RE
Merck to Acquire Imago BioSciences for $1.35 billion	21/22/21	RE
Merck & Co., Inc. entered into a definitive agreement to acquire Imago BioSciences, Inc. for $1.2 billion.	21/22/21	CI
IMAGO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	10/22/10	AQ
Imago BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Imago BioSciences Q2 Net Loss Narrows	15/22/15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Imago BioSciences, Inc.

Equities

IMGO

US45250K1079

Highlights

Filters